Published in Surgery Litigation and Law Weekly, July 13th, 2007
This trend article about Johns Hopkins University, U.S., is an immediate alert from NewsRx to identify developing directions of research.
Study 1: A new study, "Regression of chronic hypoxic pulmonary hypertension by simvastatin," is now available. "The 3-hydroxy-3-methylglutaryl CoA (HMG-CoA) reductase inhibitor, simvastatin, has been shown to attenuate chronic hypoxic pulmonary hypertension (CHPH). Here, we assess whether simvastatin is capable of inducing regression of established CHPH and explore potential mechanisms of statin effect," scientists in the United States...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Surgery Litigation and Law Weekly